A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study tests whether denileukin diftitox will deplete regulatory T cells, boost
tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or
who are ineligible for front line therapy.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio Tyler Curiel